MK-801 protects against amphetamine-induced striatal dopamine depletion in iprindole-treated rats, but not against brain serotonin depletion after p-chloroamphetamine administration.
Henderson
M G
MG
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
Hemrick-Luecke
S
S
Fuller
R W
RW
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007488:Iprindole / Q000494:pharmacology*; D051379:Mice; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D010133:p-Chloroamphetamine / Q000494:pharmacology*
D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D010133:p-Chloroamphetamine; D007488:Iprindole; D016291:Dizocilpine Maleate; D000661:Amphetamine; D004298:Dopamine; D006719:Homovanillic Acid